Explanipedia

QOL-11. C-SMART: Supporting Patients and Caregivers Through a Novel Cognitive Rehabilitation and Mindfulness Intervention Open

Sarah Braun, Ashlee R. Loughan, Michael W. Parsons, Autumn Lanoye, F. Gerard Moeller · 2025

OBJECTIVE Cognitive deficits are common in adults with primary brain tumor– negatively impacting quality of life for patients and their caregivers. Newly developed telehealth C-SMART is a mindfulness-based cognitive rehabilitation interven…

NCOG-20. Stereotactic radiation versus hippocampal avoidant whole brain radiation in patients with 5-20 brain metastases: Cognitive outcomes of 12-month survivors Open

Michael W. Parsons, Kee‐Young Shin, Jennifer Nosker, Shyam Tanguturi, Paul J. Catalano , et al. · 2025

BACKGROUND Compared to whole brain radiation (WBRT), stereotactic radiation (SRS/SRT) and Hippocampal Avoidant (HA)-WBRT produce superior neurocognitive function (NCF) outcomes for brain metastasis survivors. In a multi-center, phase 3 ran…

SURG-17. A comprehensive framework for intraoperative mapping and monitoring, and perioperative neurological, linguistic, and outcome assessment in glioma resection: Consensus recommendations from the PIONEER Consortium and RANO resect group Open

Jasper Gerritsen, Philipp Karschnia, Lorenzo Bello, Shawn L. Hervey‐Jumper, Jacob Young , et al. · 2025

BACKGROUND In diffuse glioma patients, greater extent of resection is associated with longer survival. Intraoperative mapping and monitoring are essential to maximize safe resection by identifying and preserving functional areas. Despite w…

Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma Open

John Y. Rhee, Juan Pablo Ospina Botero, Thomas Nelson, Kun Song, Michael W. Parsons , et al. · 2025

‘Pseudoprogression’ following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging resp…

OS11.6.A A COMPREHENSIVE FRAMEWORK FOR INTRAOPERATIVE MAPPING AND MONITORING, AND PERIOPERATIVE NEUROLOGICAL, LINGUISTIC, AND OUTCOME ASSESSMENT IN GLIOMA RESECTION: CONSENSUS RECOMMENDATIONS FROM THE PIONEER CONSORTIUM AND RANO RESECT GROUP Open

Jasper K W Gerritsen, Philipp Karschnia, Lorenzo Bello, Shawn L. Hervey‐Jumper, Jacob S. Young , et al. · 2025

BACKGROUND In adult patients with diffuse glioma, greater extent of resection is associated with longer overall and progression-free survival. Intraoperative mapping and monitoring techniques are essential to safely achieve maximum resecti…

Neuropsychological functioning in non-CNS cancer patients Open

Charlotte Sleurs, Julianne Reilly, Emiliano Santarnecchi, Michael W. Parsons · 2025

While these more personalized interventions might hold promise for CRCI, further research is needed to determine their true efficacy, particularly considering the potential influence of practice effects. Additionally, in-depth, large-scale…

Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas Open

Melissa M Gardner, Sebastian Winter, Franziska Stahl, Elizabeth R. Gerstner, Helen A. Shih , et al. · 2024

Purpose Radiation therapy (RT) is an integral treatment component in patients with glioma but associated with neurotoxicity. Proton RT (PRT), as compared with photon RT (XRT), reduces excess radiation to nontarget tissue. We used a retrosp…

CTNI-79. PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY TANEZUMAB IN SUBJECTS WITH MODERATE TO SEVERE PAIN DUE TO SCHWANNOMATOSIS Open

Scott R. Plotkin, Jennifer Da, Danielle Silverman, Vanessa L. Merker, Ina Ly , et al. · 2023

INTRODUCTION Schwannomatosis (SWN) is a rare neurogenetic condition (prevalence 1:125,000) characterized by multiple schwannomas and severe chronic pain. Increased expression of nerve growth factor (NGF) has been identified in painful schw…

NCOG-34. BRAIN PET IMAGING OF PAIRED HELICAL FILAMENT TAU IN OLDER ADULTS WITH CANCER: PILOT STUDY TO IDENTIFY MECHANISMS OF COGNITIVE IMPAIRMENT AFTER CANCER THERAPY Open

Michael W. Parsons, Liesel Von Imhof, Ryan Eckbo, Yuta Katsumi, Alexandra Touroutoglou , et al. · 2023

BACKGROUND Cancer-related cognitive impairment (CRCI) occurs in up to 75% of patients treated with chemotherapy for systemic cancer, and older patients treated for CNS cancer receiving brain radiation therapy (RT) and chemotherapy are part…

NCOG-48. A PROSPECTIVE LONGITUDINAL NEUROCOGNITIVE OUTCOME STUDY IN PATIENTS TREATED WITH CAR-T-CELL THERAPY AT 6 MONTHS Open

Giuliana Zarrella, Mitchell W. Lavoie, Melissa M Gardner, P. Connor Johnson, Areej El‐Jawahri , et al. · 2022

INTRODUCTION Chimeric Antigen Receptor T-cell (CAR-T) therapy carries risk of significant neurocognitive function (NCF) toxicities. Longer term NCF outcomes have yet to be reported. The goal of the current study was to assess NCF prospecti…

NCOG-09. RADIATION INDUCED CEREBRAL VOLUME LOSS AND CEREBROVASCULAR DISEASE RISK IN SURVIVORS OF GRADE 2 AND 3 GLIOMAS Open

Melissa M Gardner, Sebastian Winter, Jörg Dietrich, Elizabeth R. Gerstner, Janet C. Sherman , et al. · 2022

INTRODUCTION Cranial irradiation with protons (PRT) as compared with photons (PHT) reduces radiation exposure to healthy brain tissue and may mitigate early- and late-delayed complications. Prior work in our group has demonstrated that PRT…

RADT-24. PHASE II STUDY OF PROTON RADIATION THERAPY FOR LOWER GRADE GLIOMAS Open

J. Slater, Nora Horick, Lisa B. Nachtigall, Michael W. Parsons, Giuliana Zarrella , et al. · 2022

PURPOSE To report preliminary results on outcomes of patients with lower grade gliomas (LGG) treated with proton therapy. METHODS Patients with grade II or IDH mutant grade III glioma and indications for radiation therapy were enrolled in …

NCOG-20. BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/RTOG 0825 PARTICIPANTS Open

Oluwatosin Akintola, Jörg Dietrich, Alona Muzikansky, Melissa M Gardner, Gilbert Youssef , et al. · 2022

BACKGROUND The clinical trial NRG/RTOG 0825 sought to determine if the addition of bevacizumab to temozolomide and radiation improves survival in patients with newly diagnosed glioblastomas. Tertiary objectives included measuring the effec…

RADT-23. MODALITY-SPECIFIC CNS INJURY FOLLOWING PROTON VS PHOTON BEAM RADIOTHERAPY IN GLIOMA Open

Sebastian Winter, Melissa M Gardner, Michael W. Parsons, Clemens Grassberger, Marc R. Bussière , et al. · 2022

BACKGROUND CNS injury following brain-directed radiotherapy (RT) is common and may mimic disease progression. Dosimetric advantages of protons (PRT) over photons (XRT) minimize radiation to healthy brain, potentially limiting radiotoxic se…

P03.05.A Radiation-induced leukoencephalopathy (RIL) in glioma: unique injury dynamics following proton vs photon beam radiotherapy Open

Sebastian Winter, Matthew Gardner, Michael W. Parsons, Clemens Grassberger, M.R. Bussiere , et al. · 2022

Background White matter injury after brain-directed radiotherapy (RT), aka radiation-induced leukoencephalopathy (RIL), is common in brain tumor patients. Differentiation from progressive disease can be challenging. Dosimetric advantages o…

Design of a Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Tanezumab for Treatment of Schwannomatosis-Related Pain Open

Jennifer Da, Vanessa L. Merker, Justin T. Jordan, Ina Ly, Alona Muzikansky , et al. · 2022

NCOG-20. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN ADULTS WITH LOW GRADE GLIOMA TREATED WITH PROTON RADIATION THERAPY Open

Giuliana Zarrella, Michael W. Parsons, Janet C. Sherman, Jörg Dietrich, Helen A. Shih · 2021

INTRODUCTION Our group previously demonstrated stability in neurocognitive function (NCF) over a 5-year period after proton radiation therapy (PRT) in low grade glioma (LGG) patients. Subjective cognitive function (SCF) had not been previo…

NCOG-48. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN A BRAIN TUMOR SAMPLE: IMPROVED CORRESPONDENCE WITH NEUROPSYCHOLOGICAL PERFORMANCE OVER TIME Open

Melissa M Gardner, Giuliana Zarrella, Jörg Dietrich, Michael W. Parsons · 2021

INTRODUCTION Estimates of subjective cognitive function (SCF) generally show minimal correlation with objective measures of neurocognitive function (NCF). Our group recently validated a new metric of SCF in neuro-oncology patients, creatin…

Preservation of neurocognitive function in the treatment of brain metastases Open

Michael W. Parsons, Katherine B. Peters, Scott Floyd, Paul D. Brown, Jeffrey S. Wefel · 2021

Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the metastasis, including surgery, radiation the…

Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care? Open

Paul D. Brown, Michael W. Parsons, Chad G. Rusthoven, Vinai Gondi · 2021

Reliability and validity of a novel cognitive self-assessment tool for patients with cancer Open

Giuliana Zarrella, Alice L. Pérez, Jörg Dietrich, Michael W. Parsons · 2021

Background Subjective cognitive function is an important outcome measure in oncology. The Functional Assessment of Cancer Therapy—Brain (FACT-Br) is a quality of life (QoL) measure that includes indices of physical, emotional, social, and …

Assessment and Management of Cognitive Symptoms in Patients With Brain Tumors Open

Michael W. Parsons, Jörg Dietrich · 2021

Cognitive symptoms occur in almost all patients with brain tumors at varying points in the disease course. Deficits in neurocognitive function may be caused by the tumor itself, treatment (surgery, radiation, or chemotherapy), or other com…

Cancer, cognition, and COVID: delivering direct-to-home teleneuropsychology services to neuro-oncology patients Open

Melissa M Gardner, Farah Aslanzadeh, Giuliana Zarrella, Sarah Braun, Ashlee R. Loughan , et al. · 2021

Background The COVID-19 pandemic induced rapid adoption of telemedicine services for neuro-oncology patients at an increased risk of infection. Neuropsychological assessment is important to neuro-oncology care yet challenging to complete o…

COVD-19. COGNITION, CANCER, AND COVID: DELIVERING DIRECT-TO-HOME TELE-NEUROPSYCHOLOGY SERVICES TO NEURO-ONCOLOGY PATIENTS Open

Melissa M Gardner, Farah Aslanzadeh, Giuliana Zarrella, Sarah Braun, Ashlee R. Loughan , et al. · 2020

BACKGROUND The COVID-19 pandemic altered the delivery of healthcare services globally with a rapid adoption of telemedicine to meet patient’s needs. Telemedicine is critical for neuro-oncology patients who may be at an increased risk of in…

NCOG-70. RELIABILITY AND VALIDITY OF A NEW SELF-REPORT INDEX OF COGNITIVE CONCERNS IN BRAIN TUMOR PATIENTS Open

Giuliana Zarrella, Alice L. Pérez, Jörg Dietrich, Michael W. Parsons · 2020

INTRODUCTION Subjective cognitive dysfunction is an important outcome measure in neuro-oncology and may provide additional information beyond performance-based neuropsychological testing. The Functional Assessment of Cancer Therapy-Brain (…

Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers Open

Deborah Forst, Katharine M. Quain, Sophia Landay, Maya Anand, Emilia Kaslow-Zieve , et al. · 2020

Background Patients with malignant gliomas have a poor prognosis. However, little is known about patients’ and caregivers’ understanding of the prognosis and the primary treatment goal. Methods We conducted a prospective study in patients …

QOLP-38. PATIENT REPORTED OUTCOMES IN GLIOMA: THE ROLE OF IDH MUTATION ON QUALITY OF LIFE AND MOOD Open

Michael W. Parsons, Adomas Bunevičius, Jörg Dietrich · 2019

Isocitrate dehydrogenase 1 (IDH) mutation has important clinical prognostic value in glioma patients conferring improved survival and better neurocognitive function (NCF) compared to IDH wild type (IDH-WT) patients. It is not known whether…

INNV-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES Open

Nancy Wang, Justine V. Cohen, Nathaniel Goss, Mia Bertalan, Maura Keeley , et al. · 2019

Brain metastases (BM) are the most common tumors to affect the central nervous system (CNS). Treatment options have recently evolved with the use of new targeted therapies, immune checkpoint inhibitors, and increased access to clinical tri…

Assessment and management of cognitive changes in patients with cancer Open

Michael W. Parsons, Jörg Dietrich · 2019

Cancer‐related cognitive impairment has been a contentious issue in the past, but 2 decades of research have improved our understanding of the problem. It is time to move these advances into routine clinical care for cancer patients.

NCOG-04. EFFECTS OF PROTON RADIATION ON BRAIN STRUCTURE AND FUNCTION IN LOW GRADE GLIOMA Open

Michael W. Parsons, Katharina Hoebel, Ken Chang, Thanakit Pongpitakmetha, Andrew Beers , et al. · 2018

INTRODUCTION: Previous studies have shown progressive global brain volume loss over a 1–2 year period after treatment for glioblastoma with conventional chemoradiation. The pathogenesis of this toxicity is not well understood, though may r…

Michael W. Parsons YOU? Author Swipe